In a recent extension study of a Phase 2 trial, Anavex 2-73, developed by Anavex Life Sciences, demonstrated significant potential in reducing the
severity of symptoms in patients with Parkinson’s disease dementia. This
investigational therapy was administered to 20 participants over a one-year
period, with promising results indicating both safety and efficacy.
Anavex 2-73 is an orally available small molecule that activates the SIGMAR1 receptor, a crucial
protein involved in maintaining healthy brain cells. The absence or reduction
of SIGMAR1 has been linked to various neurodegenerative disorders, including
Parkinson’s disease, Alzheimer’s disease, and Rett syndrome. By targeting this
receptor, Anavex Life Sciences aims to provide a comprehensive treatment option
for these conditions.
During the gap between the original Phase 2 trial and the extension study, participants
experienced a noticeable worsening of symptoms. However, upon resuming Anavex
2-73 treatment, there was a marked improvement in their clinical condition. The
Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
scores, which had deteriorated during the drug holiday, showed significant
recovery by the end of the extension study.
Christopher Missling, PhD, president and CEO of Anavex
Life Sciences, highlighted the importance of these findings. “This data suggests Anavex
2-73’s potential capability to slow and potentially reverse the life-altering
symptoms of Parkinson’s disease,” he stated in a press release.
The long-term safety profile of Anavex 2-73 was consistent with previous trials, indicating
its tolerability for extended use. Encouraged by these results, Anavex Life
Sciences plans to initiate a pivotal Phase 3 trial to further evaluate the
efficacy of Anavex 2-73. The primary objective will be to assess improvements
in MDS-UPDRS scores over six months, with secondary goals including overall
health and cognitive function.
As Anavex Life Sciences continues to advance this promising therapy, the potential benefits
for patients with neurodegenerative diseases could be substantial, offering
hope for improved quality of life and symptom management. Read this article for additional information.
Like their Facebook page on https://www.facebook.com/AnavexLifeSci/